BUZZ-Rallybio jumps as UCB steps in with $2.2 bln deal for Candid

United Community Banks, Inc.
Rallybio Corporation

United Community Banks, Inc.

UCB

0.00

Rallybio Corporation

RLYB

0.00

** Shares of Rallybio RLYB.O soar 34.9% to $12.69 premarket

** UCB UCB.BR on Sunday said it would buy privately held Candid Therapeutics for up to $2.2 billion to strengthen its immunology pipeline

** In March, Rallybio announced it would merge with Candid, with the combined company retaining the Candid name and trading as CDRX

** Under that deal, Rallybio shareholders would own about 3.65% of the combined company, with Candid shareholders holding roughly 96.35%

** Before the Rallybio-Candid deal could close in mid-2026, UCB swooped in to acquire Candid

** "We see the proposed acquisition of Candid as a good strategic fit with UCB's immunology franchise" - J.P. Morgan analyst

** As of last close, RLYB up 71% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.